Bob More
Director
immunology
Immuno diagnostic systems
British Indian Ocean Territory
Biography
Bob More is a member of the board of directors at Vir. He has more than 20 years of life sciences investing experience and currently serves as managing director at Alta Partners. Most recently, he was a senior advisor for the Bill & Melinda Gates Foundation and led the Global Health Venture Initiative. Previously, he was a general partner with Frazier Healthcare Ventures and Domain Associates. He managed successful investments in and served on the boards of ESP Pharma (acquired by Protein Design Labs, Inc.), Proxima Therapeutics (acquired by Cytyc Corporation), NovaCardia (acquired by Merck), Esprit Pharma (acquired by Allergan), IntraLase (acquired by Advanced Medical Optics, Inc.), Oceana Therapeutics (acquired by Salix Pharmaceuticals), Achaogen (NASDAQ: AKAO), Neothetics, (NASDAQ: NEOT) and Glaukos Corporation (NYSE: GLKS). He was also an investor in Clovis Pharmaceuticals, Affinivax, and Sienna Labs.
Research Interest
Bob More is a member of the board of directors at Vir. He has more than 20 years of life sciences investing experience and currently serves as managing director at Alta Partners. Most recently, he was a senior advisor for the Bill & Melinda Gates Foundation and led the Global Health Venture Initiative. Previously, he was a general partner with Frazier Healthcare Ventures and Domain Associates. He managed successful investments in and served on the boards of ESP Pharma (acquired by Protein Design Labs, Inc.), Proxima Therapeutics (acquired by Cytyc Corporation), NovaCardia (acquired by Merck), Esprit Pharma (acquired by Allergan), IntraLase (acquired by Advanced Medical Optics, Inc.), Oceana Therapeutics (acquired by Salix Pharmaceuticals), Achaogen (NASDAQ: AKAO), Neothetics, (NASDAQ: NEOT) and Glaukos Corporation (NYSE: GLKS). He was also an investor in Clovis Pharmaceuticals, Affinivax, and Sienna Labs.
